Verastem Oncology’s avutometinib plus defactinib trial in LGSOC published in JCO with robust clinical responses

Verastem Oncology (NASDAQ: VSTM), a biopharmaceutical company advancing therapies for cancers driven by RAS/MAPK pathway mutations, has announced the publication of the primary results from its Phase 2 RAMP 201 trial in the Journal of Clinical Oncology. The study evaluated the efficacy and safety of avutometinib in combination with defactinib in patients with recurrent low-grade serous ovarian cancer (LGSOC). The confirmed objective response rate (ORR) stood at 31% across all evaluable patients, with especially encouraging results in the KRAS-mutated subgroup. These findings supported the accelerated U.S. FDA approval of the AVMAPKI™ FAKZYNJA™ co-pack for KRAS-mutated recurrent LGSOC on May 8, 2025.

Originally presented at the 2024 IGCS Annual Meeting, the results have since gained traction among institutional stakeholders as a meaningful advance in ovarian cancer treatment strategies. Analysts expect the findings to significantly influence future guidelines and standard-of-care recommendations.

What are the latest clinical outcomes of avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer?

The RAMP 201 trial enrolled 109 patients with recurrent LGSOC who had undergone a median of three prior treatment regimens, including chemotherapy, hormonal agents, bevacizumab, and MEK inhibitors. The confirmed ORR for all patients was 31%, broken down as 44% in those with KRAS mutations and 17% in KRAS wild-type individuals. Median progression-free survival (PFS) reached 12.9 months overall, surging to 22.0 months in the KRAS-mutant subgroup and holding at 12.8 months in the KRAS wild-type cohort.

The combination therapy demonstrated a median duration of response (DoR) of 31.1 months in the KRAS-mutated group and 9.2 months in KRAS wild-type patients. Disease control rates (DCR) at or beyond six months were recorded at 70% for KRAS-mutated patients and 50% for KRAS wild-type cases. Notably, 82% of all trial participants experienced a measurable reduction in target lesion size, regardless of KRAS mutation status.

How does the AVMAPKI and FAKZYNJA regimen differ from previous treatments for LGSOC patients?

LGSOC is a relatively rare and clinically challenging ovarian cancer subtype, known for its insidious progression and low responsiveness to conventional chemotherapy. Affecting an estimated 80,000 individuals globally, LGSOC shows high recurrence rates and is associated with significant impacts on long-term quality of life, fertility, and mental health.

What makes the AVMAPKI and FAKZYNJA combination distinct is its dual-target mechanism. Avutometinib acts by inhibiting MEK while simultaneously preventing MEK reactivation through RAF blockade. Defactinib, a FAK inhibitor, addresses drug resistance by targeting the compensatory activation of focal adhesion kinase, a downstream effect of MEK pathway inhibition. The integrated action enhances response durability and tumor control, particularly in RAS/MAPK pathway-driven malignancies.

What is the institutional response to the RAMP 201 data and how might it affect clinical practice guidelines?

Institutional sentiment toward the RAMP 201 results has been notably optimistic. The data publication in Journal of Clinical Oncology is being interpreted as a strong endorsement of the trial’s clinical rigor and therapeutic relevance. Verastem Oncology has already submitted these findings—along with those from the prior FRAME study—to the National Comprehensive Cancer Network® (NCCN®) for potential inclusion in the NCCN Clinical Practice Guidelines, particularly concerning the KRAS wild-type cohort, which currently lacks FDA-approved treatment options.

The combination regimen is already classified as an NCCN Category 2A recommendation for treating KRAS-mutated recurrent LGSOC, aligning with the recently granted FDA accelerated approval. Analysts believe that guideline expansion to include KRAS wild-type populations could considerably widen the eligible patient base and reinforce institutional adoption across oncology centers.

What safety profile was observed with avutometinib and defactinib in the Phase 2 RAMP 201 trial?

The combination of avutometinib and defactinib was generally well tolerated across the study population. Only 10% of patients discontinued treatment due to adverse events. The most common side effects included nausea (67.0%, with 2.6% Grade ≥3), diarrhea (58.3%, with 7.8% Grade ≥3), and increased creatine phosphokinase levels (60.0%, with 24.3% Grade ≥3). Other observed toxicities such as skin reactions, ocular disorders, liver enzyme elevations, and rhabdomyolysis were consistent with known pharmacological actions of MEK and FAK inhibitors and were manageable through dose adjustments and supportive care.

Importantly, the study protocol included structured monitoring schedules for liver function, ocular health, and muscle toxicity, helping to mitigate the severity and impact of adverse events. These safety results support broader use in real-world populations, provided careful baseline screening and monitoring are in place.

What are the future trial directions and regulatory milestones for avutometinib and defactinib in ovarian and other cancers?

To solidify the clinical benefit and support full regulatory approval, Verastem Oncology is currently enrolling patients in the international Phase 3 RAMP 301 trial (NCT06072781), a confirmatory study comparing avutometinib and defactinib against standard chemotherapy or hormonal therapies in patients with recurrent LGSOC regardless of KRAS mutation status. The trial, being conducted under the GOG-3097/ENGOT-ov81/GTG-UK collaborative, is expected to provide definitive evidence for broader label expansion.

Additionally, Verastem is exploring the combination in other solid tumors with high RAS/MAPK dependency. Ongoing trials include RAMP 203 in advanced KRAS G12C mutant non-small cell lung cancer (NSCLC) and RAMP 205 in advanced pancreatic cancer. These parallel efforts underscore the company’s strategic focus on drug resistance modulation via dual-pathway inhibition.

How are investors reacting to Verastem Oncology’s progress on AVMAPKI FAKZYNJA and its broader RAS pathway portfolio?

Investor sentiment surrounding Verastem Oncology has been buoyed by the positive RAMP 201 data and subsequent FDA approval. The stock (NASDAQ: VSTM) experienced a marked uptick following the May 2025 approval announcement, reflecting market confidence in the platform’s commercial potential. With continued execution in its Phase 3 program and new indications under investigation, analysts forecast that Verastem could position AVMAPKI FAKZYNJA as a foundational treatment in KRAS-mutated oncology segments.

However, the accelerated approval remains contingent on confirmatory evidence, and future success will depend on maintaining favorable reimbursement dynamics, physician uptake, and competitive differentiation. Verastem’s growing intellectual property portfolio and its strategy of targeting biologically resistant tumor types are seen as key value drivers by institutional investors.

Why is the AVMAPKI FAKZYNJA co-pack considered a breakthrough in treating KRAS-driven ovarian cancer?

The AVMAPKI FAKZYNJA co-pack has emerged as a potentially transformative option in recurrent LGSOC, especially among KRAS-mutated patients who previously lacked targeted therapies. With durable responses, manageable toxicity, and applicability in heavily pretreated populations, the regimen fills a critical unmet need in a rare and persistent ovarian cancer subtype.

By tackling both MEK pathway activation and resistance feedback loops, the dual therapy sets a new bar for combination strategy design in precision oncology. Its success in LGSOC could pave the way for similarly structured regimens across other RAS-driven tumors, signaling a new era of mechanism-informed multi-target drug development.